Ipamorelin / Tesamorelin research: quick summary
This listing pairs 5 mg of ipamorelin, a synthetic pentapeptide described at the ghrelin receptor, with 5 mg of tesamorelin, a stabilised 44-residue GHRH analogue. Tesamorelin is the active ingredient of an approved medicine elsewhere; this material is a different category of product. Neither vial is an authorized medicine, both are for laboratory research only, neither is for human or veterinary use, and no dosing or protocol information is provided.
Ipamorelin / Tesamorelin Canada: Ipamorelin 5mg / Tesamorelin 5mg Research Product
Two lyophilized research chemicals are held together under this listing, sold to qualified purchasers in Canada with both lots documented separately.
People find this page through buy Ipamorelin Tesamorelin Canada, Ipamorelin peptide Canada and Tesamorelin Canada. Those are typed queries, not offered purposes. Personal-health enquiries belong with a clinician.
Red Leaf Research Labs supplies both components as research chemicals. Neither is sold for administration to a person or an animal, no dosing or combination instruction is given, and no claim is made for either.
Ipamorelin 5mg / Tesamorelin 5mg Research Format and Options
| Attribute | Detail |
|---|
| Research format | 5 mg ipamorelin and 5 mg tesamorelin, lyophilized |
| Physical state | A dried cake in each of two sealed vials |
| Analytical documentation | An independent report for each component lot |
| Fulfilment | Domestic dispatch to research addresses |
| Intended use | Laboratory research only; not for human or veterinary use |
Two vials mean two documents. A certificate covering one of them leaves the other undescribed.
Ipamorelin / Tesamorelin Research Specifications
Component 1: ipamorelin
- Compound name: Ipamorelin
- Alternative names / shorthand: NNC 26-0161, Ipa
- Peptide/compound class: Designed pentapeptide secretagogue
- Receptor or pathway interest: The ghrelin receptor, GHS-R1a
- Structural origin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- CAS: 170851-70-4
- Molecular formula: C38H49N9O5
- Molecular weight: approximately 711.9 g/mol
Component 2: tesamorelin
- Compound name: Tesamorelin
- Alternative names / shorthand: TH9507, Tesa
- Peptide/compound class: Synthetic 44-residue GHRH analogue, N-acylated
- Receptor or pathway interest: GHRH receptor (GHRHR), pituitary
- Structural origin: Human GHRH(1-44), N-terminal trans-3-hexenoyl group
- CAS: 218949-48-5
- Molecular formula: C221H366N72O67S
- Molecular weight: approximately 5135.9 g/mol
Both components: quantity 5 mg, format lyophilized solid, use laboratory research only, fulfilment domestic Canadian dispatch.
What Is Ipamorelin / Tesamorelin?
Ipamorelin is a five-residue peptide of aminoisobutyric acid, histidine, D-2-naphthylalanine, D-phenylalanine and lysine, C-terminally amidated. Three residues are non-proteinogenic or D-configured, making it a designed construct, not a natural fragment. Tesamorelin is the opposite: the full 44-residue human GHRH sequence with a trans-3-hexenoyl group on the N-terminal tyrosine.
Ipamorelin is most often confused with GHRP-2 and GHRP-6, separate sequences with their own CAS numbers. Tesamorelin is confused with sermorelin, GHRH(1-29) amide with no acyl group, and with the CJC-1295 materials.
Ipamorelin / Tesamorelin and Growth Hormone Axis Receptor Research
The components are studied at two receptors. Raun and colleagues characterised ipamorelin at GHS-R1a in rat pituitary cells, rats and swine, reporting in the European Journal of Endocrinology in 1998 growth hormone release without the corticotropin and cortisol changes seen with GHRP-6 and GHRP-2. Tesamorelin is studied at GHRHR on the somatotroph, a class B receptor read out through cyclic AMP, its acyl group characterised against N-terminal degradation.
Those are measurements by others in cells, animal models and registered clinical programmes. Activity at a receptor in a model does not establish an effect in a person, and nothing is claimed for the pairing.
Why Buy Ipamorelin 5mg / Tesamorelin 5mg in Canada from a Domestic Research Supplier?
Two vials mean two thermal histories, and the 44-residue component has far more bonds exposed to the route.
The second reason is regulatory hygiene. One molecule here is an authorised medicine elsewhere, so the line between reagent and product needs drawing by someone answerable here.
Route length changes no composition. Only the two certificates describe what shipped.
How This Ipamorelin / Tesamorelin Canada Page Improves on Typical Competitor Listings
Paired listings are where template copy shows. Five things separate this one.
- Each molecule carries its own CAS number, formula and mass, set out apart from the other.
- Documentation is described component by component, each keyed to its own lot code.
- Neither component is credited with an effect, a benefit or a safety property.
- The regulatory position is explicit: tesamorelin is approved elsewhere, this is a different category.
- Structural relationships are named, separating ipamorelin from the GHRPs and tesamorelin from sermorelin.
How to Evaluate an Ipamorelin / Tesamorelin Certificate of Analysis
Two certificates, two unlike molecules. The larger carries a trans-3-hexenoyl group on its N-terminal tyrosine, and that group is what its document must prove.
- Compound identity: ipamorelin at CAS 170851-70-4, tesamorelin at CAS 218949-48-5.
- Lot reference: each document carries its own vial’s lot.
- Analysis date: a testing date per component, against each manufacturing date.
- Test methods: per component, the acylated peptide needing separation from its deacylated form.
- Measured quantity: 5 mg accounted for on each certificate.
- Purity result: one figure per component, with its method.
- Laboratory verification: the analysing laboratory named for each.
The finer question sits on the larger component: losing the hexenoyl group leaves a mass about 96 daltons lower.
Ipamorelin 5mg / Tesamorelin 5mg Lyophilized Research Format
Each vial is freeze-dried, the ice leaving as vapour under vacuum so the peptide bonds sit dry rather than in water.
The two behave differently once handled. The pentapeptide is small and largely non-natural, with few labile positions; the 44-residue component has many more, including the N-terminal acyl group stability work attends to. Each vial needs its own record, and a supplier note requires advanced reconstitution technique, meaning a validated institutional procedure.
Working out concentration for this vial? Our peptide reconstitution calculator converts vial size and bacteriostatic water volume into mg per mL and U-100 syringe units.
How to Buy Ipamorelin / Tesamorelin in Canada for Qualified Research
- Confirm eligibility. Confirm your organization may receive a molecule marketed elsewhere as a medicine.
- Review documentation. Read both certificates; one leaves the pairing half described.
- Select quantity. Fix the number of pairings from the plan.
- Check shipping route. Confirm route and window against receiving hours.
- Record receipt. Log both lot numbers, the date and each condition.
Purchasing and records only; no dosing or study-design advice attaches.
Ipamorelin / Tesamorelin Availability in Canada: Research vs. Consumer Searches
This listing sits closer to an approved medicine than most. Tesamorelin is the active ingredient of Egrifta, from Theratechnologies of Montreal, approved in the United States in 2010 and by Health Canada in 2014. One name covers two different things.
An approved medicine is a finished pharmaceutical product: a specified formulation made to pharmaceutical standards, labelled and dispensed under prescription. This vial is none of those, has not been assessed by Health Canada, and is not a version of it. Ipamorelin has no approved status anywhere.
A personal-health interest in tesamorelin belongs with a licensed clinician. This listing is not a route to a prescription medicine.
Ipamorelin 5mg / Tesamorelin 5mg Canada Procurement Checklist
| Check | What to confirm |
|---|
| Purpose | Laboratory research where the organization may hold both molecules |
| Identity | CAS 170851-70-4 and 218949-48-5, each on its own paperwork |
| Distinctness | The GHRH component is the acylated 44-mer, not sermorelin |
| Quantity | 5 mg documented for each vial separately |
| Documentation | Separation from the deacylated form shown for the 44-mer |
| Verification | Whether outside analysis covers one or both |
| Handling | One record per vial, plus a validated reconstitution procedure |
Explore Ipamorelin / Tesamorelin Research Information
Background reading: buying research peptides legally in Canada, third-party testing, and how peptides work.
Ipamorelin / Tesamorelin research FAQ
Does Red Leaf Research Labs provide dosing information?
No. No dosing, reconstitution volume, concentration, route, protocol or combination guidance is provided.
Is this tesamorelin the same as the approved medicine?
No. The molecular name is shared, but an approved pharmaceutical product and a research chemical are different categories of goods.
Why does a blend listing need two certificates of analysis?
Because one report characterises one material. A document naming ipamorelin is silent on the 44-residue component.
Are the two components the same class of compound?
No. Ipamorelin is a pentapeptide described at GHS-R1a; tesamorelin is a GHRH analogue at GHRHR.
Can Red Leaf Research Labs advise on using the two together?
No. Whether the two are used together, and in what order, is the laboratory’s decision.
Research use only. Ipamorelin 5 mg and tesamorelin 5 mg are supplied strictly for laboratory research. Neither vial is an authorized medicine in Canada, neither is for human or veterinary use, and no dosing or protocol information accompanies them. Personal-health questions belong with a licensed clinician.
Independent third-party testing
Janoshik Lab Reports
Review available analytical reports associated with this product.
ANALYTICAL
REPORT
Independent analysis
Ipamorelin
- Purity
- 99.848%
- Tested quantity
- 10.33 mg
- Report date
- March 25, 2026
- Task ID
- #123269
ANALYTICAL
REPORT
Independent analysis
Tesamorelin
- Purity
- 99.401%
- Tested quantity
- 10.39 mg
- Report date
- March 25, 2026
- Task ID
- #123266
A certificate describes the submitted sample shown in that report. It does not establish clinical safety, efficacy, or suitability for human or veterinary use.
Owned and operated by a cf veteran 
